As previously reported, Wells Fargo upgraded Amgen (AMGN) to Overweight from Equal Weight with a price target of $265, down from $275. The firm thinks the pessimism related to Amgen post Horizon Therapeutics (HZNP) deal has caused weakness, and now sees the stock trading 7%-8% below the worst case scenario. Amgen’s marketing strength makes worst case less likely.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AMGN:
- Amgen upgraded to Overweight from Equal Weight at Wells Fargo
- Cantor biopharma/biotech analysts to hold analyst/industry conference call
- AMGEN ANNOUNCES 2023 SECOND QUARTER DIVIDEND
- Amgen to present new Repatha combined data from Phase 3 FOURIER trials
- Horizon Therapeutics reports Q4 EPS $1.21, consensus $1.09